Neurological manifestations of IgM dysglobulinemia;Dysglobulinémies IgM et complications neurologiques

Revue Neurologique

Volumn 158, Issue 10 I, 2002, Pages 971-978

  Steck, A J ^a   Kuntzer, T ^a  

^a Neurologische Universitatsklinik Basel   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; IMMUNOLOGIC AGENT; MONOCLONAL ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN;

ADULT; AGED; BLOOD VISCOSITY; CASE REPORT; DEMYELINATING DISEASE; DRUG EFFICACY; DYSGLOBULINEMIA; HUMAN; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROLOGIC DISEASE; PARAPROTEINEMIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; REVIEW; SIDE EFFECT;

AGED; BLOOD VISCOSITY; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; NERVOUS SYSTEM DISEASES; PARAPROTEINEMIAS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0036808245     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Antoine JC, Steck A, Michel D. (1993). Neuropathie périphérique avec atteinte motrice prédominante associée à une gammapathie IgM monoclonale anti-MAG. Rev Neurol (Paris), 149:496-9.
2. Attarian S, Azulay JP, Boucraut J, Escande N, Pouget J. (2001). Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol, 112: 457-63.
3. Bing J, Neel A. (1936). Two cases of hyperglobulinemia with affection of the central nervous system on a toxi-infection basis. Acta Med Scand, 88: 492-506.
4. Bollensen E, Schachner M. (1987). The peripheral myelin glycoprotein PO expresses the L2/HNK-1 and L3 carbohydrate structures shared by neural adhesion molecules. Neurosci Lett, 82: 77-82.
5. Chassande B, Leger JM, Younes-Chennoufi AB, et al. (1998). Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve, 21: 55-62.
6. Civit T, Coulbois S, Baylac F, Taillandier L, Auque J. (1997). (Waldenstrom's macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and Neel syndrome. Apropos of a new case). Neurochirurgie, 43: 245-9.
7. Cocito D, Isoardo G, Ciaramitaro P, et al. (2001). Terminal latency index in polyneuropathy with IgM paraproteinemia and anti-MAG antibody. Muscle Nerve, 24: 1278-82.
8. Coull BM, Beamer N, De Garmo P, et al. (1991). Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke, 22: 162-8.
9. Delgado J, Canales MA, Garcia B, Alvarez-Ferreira J, Garcia-Grande A, Hernandez-Navarro F. (2002). Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature. Am J Hematol, 69: 127-31.
10. Diaz-Arrastia R, Younger DS, Hair L et al. (1992). Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology, 42: 1136-1141.
11. Dimopoulos MA, Alexanian R. (1994). Waldenstrom's macroglobulinemia. Blood, 83: 1452-1459.
12. Fain O, Wechsler B, Vidailhet M, Raphael M, Schuller E, Godeau P. (1992). Atteinte des fonctions supérieures révélant une maladie de Waldenström: Mise en évidence d'une sécrétion intrathécale d'immunoglobuline. Rev Med Interne, 13: 58-60.
13. Gabriel CM, Gregson NA, Wood NW, Hughes RA. (2002). Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a). J Neurol Neurosurg Psychiatry, 72: 230-235.
14. Gabriel JM, Erne B, Bernasconi L et al. (1998). Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy. Acta Neuropathol (Berl), 95: 540-546.
15. Ince PG, Shaw PJ, Fawcett PR, Bates D. (1987). Demyelinating neuropathy due to primary IgM kappa B cell lymphoma of peripheral nerve. Neurology, 37: 1231-1235.
16. Jammes T, Mann C, Delhom E et al. (1990). Syndrome de Bing et Neel révélé par une hydrocéphalie à pression normale. Evolution inhabituelle d'une maladie de Waldenström. Presse Med, 19: 1992.
17. Jelloun-Dellagi S, Dellagi K, Burger D et al. (1992). Childhood peripheral neuropathy with autoantibodies to myelin glycoprotein P0. Ann Neurol, 32: 700-702.
18. Jungalwala FB. (1994). Expression and biological functions of sulfoglucuronyl glycolipids (SGGLs) in the nervous systema review. Neurochem Res, 19: 945-957.
19. Kaku DA, England JD, Sumner AJ. (1994). Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain, 117: 941-947.
20. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. (2000). Distal acquired demyelinating symmetric neuropathy. Neurology, 54: 615-620.
21. Kelly JJ. (1998). Polyneuropathies associated with myeloma, POEMS, and non-malignant IgG and IgA monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ, editors. Immunological and Infectious Diseases of the Peripheral Nerves. Cambridge: Cambridge university press, pp: 225-37.
22. Koller H, Von Giesen HJ, Siebler M. (1995). Impairment of electrophysiological function of astrocytes by cerebrospinal fluid from a patient with Waldenstrom's macroglobulinemia. J Neuroimmunol, 61: 35-39.
23. Kuntzer T, Lobrinus JA, Janzer RC, Ghika J, Bogousslavsky J. (2000). Clinicopathological and molecular biological studies in a patient with neurolymphomatosis. Muscle Nerve, 23: 1604-1609.
24. Kuntzer T, Talamon C, Said G. (1998). Neuropathie périphérique progressive chez un homme de 64 ans. Rev Neurol (Paris), 154: 789-794.
25. Kwa MS, Van Schaik IN, Brand A, Baas F, Vermeulen M. (2001). Investigation of serum response to PMP22, connexin 32 and P(0), in inflammatory neuropathies. J Neuroimmunol, 116: 220-225.
26. Kyle RA, Therneau TM, Rajkumar SV et al. (2002). A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med, 346: 564-569.
27. Lee G, Ware RR, Latov N. (1994). Somatically mutated member of the human V lambda VIII gene family encodes anti-myelin-associated glycoprotein (MAG) activity. J Neuroimmunol., 51: 45-52.
28. Levine TD, Pestronk A. (1999). IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology, 52: 1701-1704.
29. Logothetis J, Silverstein P, Coe J. (1960). Neurological aspects of Waldenström's macroglobulinemia. Arch Neurol, 3: 564-573.
30. Manschot SM, Notermans NC, Van den Berg LH, Verschuuren JJ, Lokhorst HM. (2000). Three families with polyneuropathy associated with monoclonal gammopathy. Arch Neurol, 57: 740-742.
31. Mariette X, Brouet JC, Chevret S et al. (2000). A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry, 69: 279-280.
32. Mariette X, Tsapis A, Brouet JC. (1993). Nucleotidic sequence analysis of the variable domains of four human monoclonal IgM with an antibody activity to myelin-associated glycoprotein. Eur. J Immunol., 23: 846-851.
33. Martyn CN, Hughes RA. (1997) Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry, 62: 310-318.
34. Monteiro L, Wildi E. (1975). Macroglobulinémie de Waldenström avec atteinte lymphoproliférative du système nerveux central (syndrome de Bing et Neel). A propos de 4 observations anatomo-cliniques. Arch Sui Neurol Neurochir Psychiatr, 116: 59-82.
35. Nemni R, Corbo M, Fazio R, Quattrini A, Comi G, Canal N. (1988). Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain, 111: 541-552.
36. Nobile-Orazio E. (1998). Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ, editors. Immunological and Infectious Diseases of the Peripheral Nerves. Cambridge: Cambridge university press,: pp168-89.
37. Nobile-Orazio E, Barbieri S, Baldini L et al. (1992). Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand, 85: 383-390.
38. Nobile-Orazio E, Carpo M. (2001)Neuropathy and monoclonal gammopathy. (Review). (53 refs). Current Opinion in Neurology, 14: 615-620.
39. Nobile-Orazio E, Manfredini E, Carpo M et al. (1994). Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol, 36: 416-424.
40. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. (2000) Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain, 123: 710-717.
41. Notermans NC, Franssen H, Eurelings M, Van der Graaf, Wokke JH. (2000). Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy. Muscle Nerve, 23: 73-79.
42. Odabasi Z, Parrott JH, Reddy VV, Oh SJ. (2001). Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: A case report and review of literature. J Peripher Nerv Syst, 6: 197-203.
43. Onrust SV, Lamb HM, Balfour JA. (1999). Rituximab. Drugs, 58: 79-88.
44. Paterson RL, Kelleher CA, Streib JE et al. (1995). Activation of human thymocytes after infection by EBV. J Immunol., 154: 1440-1449.
45. Ponsford S, Willison H, Veitch J, Morris R, Thomas PK. (2000) Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. Neurology, 56: A399 Suppl 3.
46. Quarles RH. (1997) Glycoproteins of myelin sheaths. J Mol. Neurosci., 8: 1-12.
47. Radziwill AJ, Steck AJ, Renaud S, Fuhr P. (2002). Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathy. Neurology, 56: A399 Suppl 3.
48. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2001). Rituximab and anti-MAG-associated polyneuropathy: A pilot study. Neurology, 56(8): A396 Suppl. 3.
49. Richards AI. (1995). Response of meningeal Waldenstrom's macroglobulinemia to 2-chlorodeoxyadenosine. J Clin Oncol, 13: 2476.
50. Ritz MF, Lechner-Scott J, Scott RJ et al. (2000). Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies. J Neuroimmunol., 104: 155-163.
51. Saleun JP, Vicariot M, Deroff P, Morin JF. (1982). Monoclonal gammopathies in the adult population of Finistere, France. J Clin. Pathol., 35: 63-68.
52. Scheithauer BW, Rubinstein LJ, Herman MM. (1984)Leukoencephalopathy in Waldenstrom's macroglobulinemia. Immunohistochemical and electron microscopic observations. J Neuropathol. Exp. Neurol, 43: 408-425.
53. Shamshiev A, Donda A, Prigozy TI et al. (2000). The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity., 13: 255-264.
54. Shiina M, Kusunoki S, Miyazaki T, Kanazawa I. (2001). Variability in immunohistochemistries of IgM I proteins binding to sulfated glucuronyl paragloboside. J Neuroimmunol, 116(2): 206-212.
55. Sindou P, Anani T, Garbay B, Couratier P, Lagrange E, Vallat JM. (1999b)(The involvement of myelin proteins in hereditary neuropathies). Rev Neurol (Paris), 155: 97-110.
56. Sindou P, Vallat JM, Chapon F et al. (1999a). Ultrastructural protein zero expression in Charcot-Marie-Tooth type 1B disease. Muscle Nerve, 22:99-104.
57. Snipes GJ, Suter U, Shooter EM. (1993). Human peripheral myelin protein-22 carries the L2/HNK-1 carbohydrate adhesion epitope. J Neurochem., 61: 1961-1964.
58. Steck AJ, Murray N, Meier C, Page N, Perruisseau G. (1983). Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology, 33: 19-23.
59. Stern TA, Purcell JJ, Murray GB. (1985). Complex partial seizures associated with Waldenstrom's macroglobulinemia. Psychosomatics, 26: 890-892.
60. Tagawa Y, Yuki N, Hirata K. (2000). Anti-SGPG antibody in CIDP: Nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Muscle Nerve, 23: 895-899.
61. Tedder TF, Isaacs CM. (1989). Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol., 143: 712-717.
62. Toepfer M, Schroeder M, Muller-Felber W et al. (2000). Successful management of polyneuropathy associated with IgM gammopathy of undetermined significance with antibody-based immunoadsorption. Clin. Nephrol., 53: 404-407.
63. Tommasi M, Revol L, Schott B, Lesbros F. (1966). Macroglobulinémie de Waldenström. Lésions du système nerveux central. Ann Anat Pathol (Paris), 11: 309-314.
64. Treon SP, Anderson KC. (2000) The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin. Oncol., 27: 79-85.
65. Trojaborg W, Hays AP, van den BL, Younger DS, Latov N. (1995). Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve, 18: 730-735.
66. Vital A, Lagueny A, Julien J et al. (2000). Chronic inflammatory demyelinating polyneuropathy associated with dysglobulinemia: A peripheral nerve biopsy study in 18 cases. Acta Neuropathol. (Berl), 100: 63-68.
67. Vital A, Vital C, Julien J, Baquey A, Steck AJ. (1989). Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol. (Berl), 79:160-167.
68. Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. (1993). Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci., 114: 193-199.
69. Waldenstrom JG. (1986). Macroglobulinemia - A review. Haematologica, 71: 437-440.
70. Wicklund MP, Kissel JT. (2001). Paraproteinemic Neuropathy. Curr Treatment Options Neurol, 3: 147-156.
71. Willison HJ, Kennedy PG. (1993). Gangliosides and bacterial toxins in Guillain-Barre syndrome. J Neuroimmunol., 46: 105-112.
72. Willison HJ, O'Leary CP, Veitch J et al. (2001) The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain, 124: 1968-1977.
73. Woimant F, Schanen A, Bertail MA et al. (1985) Myélopathie cervicale révélatrice d'une macroglobulinémie. Ann Med Interne (Paris), 136: 121-124.
74. Yeung KB, Thomas PK, King RH et al. (1991). The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol, 238: 383-391.
75. Yuki N, Yamamoto T, Hirata K. (1998). Correlation between cytomegalovirus infection and IgM anti-MAG/SGPG antibody-associated neuropathy. Ann Neurol, 44: 408-410.